{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:32:29Z","timestamp":1793892749849,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s13760-026-03179-6","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T07:46:05Z","timestamp":1787384765000},"page":"2047-2054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Age-stratified clinical characteristics and disability outcomes in neuromyelitis optica spectrum disorder: A cross-sectional study"],"prefix":"10.1007","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3756-2985","authenticated-orcid":false,"given":"Omid","family":"Mirmosayyeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehra","family":"Fekri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9112-9544","authenticated-orcid":false,"given":"Mohammad","family":"Yazdan Panah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Vaheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6960-1265","authenticated-orcid":false,"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"issue":"2","key":"3179_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/biomedicines7020042","volume":"7","author":"MA Lana-Peixoto","year":"2019","unstructured":"Lana-Peixoto MA, Talim N (2019) Neuromyelitis optica spectrum disorder and anti-MOG syndromes. Biomedicines 7(2):42","journal-title":"Biomedicines"},{"issue":"8","key":"3179_CR2","doi-asserted-by":"publisher","first-page":"e3644","DOI":"10.1002\/brb3.3644","volume":"14","author":"H Noori","year":"2024","unstructured":"Noori H et al (2024) Neuromyelitis optica spectrum disorder: Exploring the diverse clinical manifestations and the need for further exploration. Brain Behav 14(8):e3644","journal-title":"Brain Behav"},{"key":"3179_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jchemneu.2019.01.012","volume":"97","author":"Y Wu","year":"2019","unstructured":"Wu Y, Zhong L, Geng J (2019) Visual impairment in neuromyelitis optica spectrum disorders (NMOSD). J Chem Neuroanat 97:66\u201370","journal-title":"J Chem Neuroanat"},{"issue":"10","key":"3179_CR4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","volume":"20","author":"A Uzawa","year":"2024","unstructured":"Uzawa A et al (2024) NMOSD and MOGAD: an evolving disease spectrum. Nat Reviews Neurol 20(10):602\u2013619","journal-title":"Nat Reviews Neurol"},{"key":"3179_CR5","doi-asserted-by":"crossref","unstructured":"Panah MY, Mirmosayyeb O, Vaheb S, Rafiei N, Ghaffary EM, Mahmoudi F, Nelson F, Shaygannejad V (2025) Cognitive performances in people with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord 106921","DOI":"10.1016\/j.msard.2025.106921"},{"issue":"4","key":"3179_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/biom12040591","volume":"12","author":"Y Abe","year":"2022","unstructured":"Abe Y, Yasui M (2022) Aquaporin-4 in neuromyelitis optica spectrum disorders: a target of autoimmunity in the central nervous system. Biomolecules 12(4):591","journal-title":"Biomolecules"},{"issue":"8","key":"3179_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1080\/14712598.2021.1884223","volume":"21","author":"N Asavapanumas","year":"2021","unstructured":"Asavapanumas N, Tradtrantip L, Verkman AS (2021) Targeting the complement system in neuromyelitis optica spectrum disorder. Expert Opin Biol Ther 21(8):1073\u20131086","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"3179_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","volume":"96","author":"V Papp","year":"2021","unstructured":"Papp V et al (2021) Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology 96(2):59\u201377","journal-title":"Neurology"},{"key":"3179_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fped.2020.00339","volume":"8","author":"S Tenembaum","year":"2020","unstructured":"Tenembaum S, Yeh EA, Consortium G-JFIC (2020) Pediatric NMOSD: a review and position statement on approach to work-up and diagnosis. Front Pead 8:339","journal-title":"Front Pead"},{"issue":"13","key":"3179_CR10","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1177\/1352458516685416","volume":"23","author":"JM Seok","year":"2017","unstructured":"Seok JM et al (2017) Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: a multicenter retrospective study in Korea. Multiple Scler J 23(13):1748\u20131756","journal-title":"Multiple Scler J"},{"issue":"4","key":"3179_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/00207454.2016.1254630","volume":"127","author":"L-J Zhang","year":"2017","unstructured":"Zhang L-J et al (2017) Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders. Int J Neurosci 127(4):334\u2013338","journal-title":"Int J Neurosci"},{"issue":"2","key":"3179_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40120-019-0143-2","volume":"8","author":"YD Fragoso","year":"2019","unstructured":"Fragoso YD et al (2019) Late onset of neuromyelitis optica spectrum disorders. Neurol therapy 8(2):477\u2013482","journal-title":"Neurol therapy"},{"key":"3179_CR13","doi-asserted-by":"publisher","first-page":"1056944","DOI":"10.3389\/fimmu.2022.1056944","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu Y et al (2022) Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder. Front Immunol 13:1056944","journal-title":"Front Immunol"},{"issue":"6","key":"3179_CR14","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s10072-023-06617-y","volume":"44","author":"S Bagherieh","year":"2023","unstructured":"Bagherieh S et al (2023) Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis. Neurol Sci 44(6):1905\u20131915","journal-title":"Neurol Sci"},{"issue":"1","key":"3179_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S et al (2020) Neuromyelitis optica. Nat Reviews Disease Primers 6(1):85","journal-title":"Nat Reviews Disease Primers"},{"issue":"1","key":"3179_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12883-015-0417-y","volume":"15","author":"Z Mao","year":"2015","unstructured":"Mao Z et al (2015) Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositive patients in a Chinese population. BMC Neurol 15(1):160","journal-title":"BMC Neurol"},{"key":"3179_CR17","doi-asserted-by":"crossref","unstructured":"Thongmee W et al (2021) Comparison of early-and late-onset NMOSD-related optic neuritis in Thai patients: clinical characteristics and long-term visual outcomes. Clin Ophthalmol 15:419\u2013429","DOI":"10.2147\/OPTH.S295769"},{"issue":"6","key":"3179_CR18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135(6):1834\u20131849","journal-title":"Brain"},{"key":"3179_CR19","doi-asserted-by":"publisher","first-page":"103845","DOI":"10.1016\/j.msard.2022.103845","volume":"63","author":"E Santos","year":"2022","unstructured":"Santos E et al (2022) Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: anti-AQP4 positive, anti-MOG positive and seronegative subgroups. Multiple Scler Relat Disorders 63:103845","journal-title":"Multiple Scler Relat Disorders"},{"key":"3179_CR20","doi-asserted-by":"publisher","first-page":"111210","DOI":"10.1016\/j.jocn.2025.111210","volume":"135","author":"EM Ghaffary","year":"2025","unstructured":"Ghaffary EM et al (2025) Clinical and psychological factors associated with fear of relapse in people with multiple sclerosis: A cross-sectional study. J Clin Neurosci 135:111210","journal-title":"J Clin Neurosci"},{"issue":"5","key":"3179_CR21","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3390\/jcm9051326","volume":"9","author":"O Mirmosayyeb","year":"2020","unstructured":"Mirmosayyeb O et al (2020) Clinical characteristics and disability progression of early-and late-onset multiple sclerosis compared to adult-onset multiple sclerosis. J Clin Med 9(5):1326","journal-title":"J Clin Med"},{"issue":"9","key":"3179_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","volume":"78","author":"P Waters","year":"2012","unstructured":"Waters P et al (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78(9):665\u2013671","journal-title":"Neurology"},{"issue":"11","key":"3179_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131444","journal-title":"Neurology"},{"key":"3179_CR24","doi-asserted-by":"publisher","first-page":"859276","DOI":"10.3389\/fneur.2022.859276","volume":"13","author":"J Yu","year":"2022","unstructured":"Yu J et al (2022) Relatively early and late-onset neuromyelitis optica spectrum disorder in central China: clinical characteristics and prognostic features. Front Neurol 13:859276","journal-title":"Front Neurol"},{"key":"3179_CR25","doi-asserted-by":"publisher","first-page":"120039","DOI":"10.1016\/j.jns.2021.120039","volume":"431","author":"A Papathanasiou","year":"2021","unstructured":"Papathanasiou A et al (2021) Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. J Neurol Sci 431:120039","journal-title":"J Neurol Sci"},{"key":"3179_CR26","first-page":"e607","volume-title":"Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus","author":"M Sepulveda","year":"2019","unstructured":"Sepulveda M et al (2019) Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus, vol 6. Neuroimmunology & Neuroinflammation, Neurology, p e607. 6"},{"key":"3179_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fcell.2020.00190","volume":"8","author":"TC Sutherland","year":"2020","unstructured":"Sutherland TC, Geoffroy CG (2020) The influence of neuron-extrinsic factors and aging on injury progression and axonal repair in the central nervous system. Front cell Dev biology 8:190","journal-title":"Front cell Dev biology"},{"issue":"5","key":"3179_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.smim.2012.09.001","volume":"24","author":"J Nikolich-\u017dugich","year":"2012","unstructured":"Nikolich-\u017dugich J (2012) The aging immune system: challenges for the 21st century. Semin Immunol 24(5):301\u2013302","journal-title":"Semin Immunol"},{"key":"3179_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.msard.2018.12.011","volume":"28","author":"MA Mealy","year":"2019","unstructured":"Mealy MA et al (2019) Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Multiple Scler Relat disorders 28:64\u201368","journal-title":"Multiple Scler Relat disorders"},{"issue":"5","key":"3179_CR30","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","volume":"142","author":"J Palace","year":"2019","unstructured":"Palace J et al (2019) Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain 142(5):1310\u20131323","journal-title":"Brain"},{"issue":"12","key":"3179_CR31","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","volume":"82","author":"A Nagaishi","year":"2011","unstructured":"Nagaishi A et al (2011) Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry 82(12):1360\u20131364","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"14","key":"3179_CR32","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","volume":"80","author":"L Matthews","year":"2013","unstructured":"Matthews L et al (2013) Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80(14):1330\u20131337","journal-title":"Neurology"},{"issue":"1","key":"3179_CR33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/brain\/awaa347","volume":"144","author":"R Mariano","year":"2021","unstructured":"Mariano R et al (2021) Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis. Brain 144(1):198\u2013212","journal-title":"Brain"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03179-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03179-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03179-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:51:27Z","timestamp":1793890287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03179-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["3179"],"URL":"https:\/\/doi.org\/10.1007\/s13760-026-03179-6","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used ChatGPT in order to improve the readability and language of the manuscript. After using this service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of Isfahan University of Medical Sciences approved the research protocol (IR.ARI.MUI.REC.1401.061). All procedures conformed to the ethical standards in the 1964 Helsinki Declaration. Informed consent was secured from all participants in this study.","order":4,"name":"Ethics","label":"Human Ethics and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}